ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
November 05 2012 - 2:15PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer therapeutics
using its antibody expertise and Targeted Antibody Payload (TAP)
technology, today announced that the following presentations by
Company management at upcoming investor conferences will be
webcast:
- Lazard Capital Markets
9th Annual Healthcare Conference3:00 pm ET on
November 14, 2012 in New York, NYPresenter: Gregory Perry,
Executive Vice President and CFO
- Jefferies 2012 Global Healthcare
Conference in London10:00 am GMT (5:00 am ET) on November 15,
2012 in London, EnglandPresenter: Daniel Junius, President and
CEO
A webcast of each presentation can be accessed live through the
“Investor Information” section of the Company’s website,
www.immunogen.com; a replay of each presentation will be available
at the same location for one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company's TAP technology uses monoclonal antibodies to deliver one
of ImmunoGen's proprietary cancer-killing agents specifically to
tumor cells. There are now ten TAP compounds in clinical
development, of which three are wholly owned by the Company.
ImmunoGen’s collaborative partners include Amgen, Bayer HealthCare,
Biotest, Lilly, Novartis, Roche, and Sanofi. Marketing applications
for trastuzumab emtansine (T-DM1), the most advanced compound using
ImmunoGen’s TAP technology, have been submitted in the US and
Europe. Roche is developing this compound under an agreement
between ImmunoGen and Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024